Vistagen Therapeutics ($VTGN): What Is Left of Fasedienol After PALISADE-4, and What Happens Before February 1, 2027?

01 Bull, base and bear scenarios

A constructive scenario requires a prospective development path that builds on the positive PALISADE-2 result and tests the severe-patient or repeated-use hypotheses in a controlled setting. FDA feedback would need to translate into an implementable protocol, and financing would need to cover the study without exhausting the remaining operating budget. Safety exposure may reduce one uncertainty but does not establish efficacy.

A middle scenario is additional analysis and regulatory discussion before a funded trial begins. In that case, the stock could react to incremental updates while the central question remains unresolved: can a new randomized study reproduce a clinically useful effect? A stable narrative is not the same as stable cash, because salaries, development work and corporate obligations continue.

An adverse scenario includes an unacceptable or unaffordable trial design, weak prospective results, inability to fund the program on workable terms, or listing difficulties. A capital raise could extend operations while diluting existing owners; a reverse split could address price mechanics without creating cash or changing the molecule’s evidence. No scenario probability or price target is assigned.

What would change this reading

The clinical caution would need revision if a prospectively specified, adequately controlled study demonstrated reproducible benefit in the intended population and the company provided a credible regulatory route. Another open-label improvement alone would add descriptive evidence but would not answer the placebo-controlled question. Conversely, a further failed randomized result or regulator rejection of the proposed design would weaken the development case.

The funding assessment would improve with disclosed, usable proceeds or a binding collaboration that materially supports the planned work. Nominal ATM capacity and potential milestones are insufficient. Updated cash use and actual trial commitments could also alter the runway calculation. The listing assessment changes with a documented Nasdaq compliance decision or a new formal notice, rather than a brief move in the intraday share price.

02 The fasedienol programme, trial by trial

Fasedienol has been tested in social anxiety disorder in four randomised controlled trials and one exploratory repeat-dose study, alongside two open-label extensions and a terminated long-term safety study. The trials summarized here used the same primary endpoint: the least-squares mean change from baseline in patient-rated SUDS, a 0 to 100 distress scale, during a five-minute simulated public-speaking challenge. Reading the programme is a matter of holding the one positive result apart from the four that were not.

Two framing points belong with that table. The trial that worked is the smallest of the randomised set and the only one that did not run to its planned size, delivering its p=0.0153 on 141 patients against a protocol calling for 208. The two larger trials that followed it, each enrolling 238, both produced a point estimate on the wrong side of placebo. The programme’s arithmetic is therefore one positive on 141 patients against three negatives on 224, 238 and 238.

The open-label extensions, and what they are not

Both PALISADE extensions have reported, and both are open-label and uncontrolled, so neither bears on whether the controlled trials met their endpoints. The PALISADE-4 extension, safety population N=322 at a data cut of July 24, 2026, showed discontinuation due to adverse events of 1.6 per cent (5 of 322), none attributed to fasedienol, more than 95 per cent of events mild or moderate, headache in 18.0 per cent, upper respiratory tract infection in 9.9 per cent and no fasedienol-related serious adverse events; its LSAS series runs from a baseline mean of 99.3 (n=320) to a mean improvement of 31.4 at four months (n=197, with 65 per cent achieving at least a 20-point improvement). The PALISADE-3 extension, safety population n=341 at a cut of May 8, 2026, showed discontinuation due to adverse events of 2.6 per cent (9 of 341), with only upper respiratory tract infection at 11.4 per cent and headache at 10.9 per cent above 5 per cent.

Monthly OLE counts cannot be interpreted as if every missing observation were an adverse-event withdrawal. The company closed PALISADE-4 in July for business reasons after reporting sufficient minimum safety exposure; some participants had not yet had time to reach four months. The earlier long-term safety study, NCT05030350, was also terminated for business reasons according to its registry, which lists 481 participants. These administrative facts do not create a controlled efficacy comparison.

Cumulative exposure, and the caveat attached to it

As of May 31, 2026, Vistagen reported more than 1,500 people with at least one exposure, more than 300 with at least six months and more than 100 with at least twelve months. It considered minimum ICH E1 exposure recommendations met. The June filing nevertheless said specific exposure requirements for a possible NDA had not yet been aligned with FDA. The distinction matters: a sponsor count is not a regulator determination that all safety evidence is sufficient.

What the comparisons actually test

The positive PALISADE-2 primary contrast was a 5.8-point greater mean improvement with treatment than placebo. Both arms improved, so quoting the 13.8-point active-arm change alone would overstate the estimated treatment contribution. In PALISADE-4 the active arm improved 9.5 points but placebo improved 11.4 points; an active-arm improvement is therefore compatible with a failed comparison. The studies use different change-score conventions, so each result is presented as reported by its source rather than pooled into a new combined estimate.

Adding sample sizes across these studies would not yield a valid meta-analysis. Enrollment, stopping decisions, analysis details and clinical context differ. The 141-person positive trial was stopped after a pause following PALISADE-1; the company explained its decision in terms of time, cost and methodological complexity, despite an interim analysis that did not indicate futility. That history belongs beside the result, but it does not mathematically erase the reported significance.

The PALISADE-4 very-severe subset contained 123 of 238 participants, about 51.7% of the overall population. Its 9.1-point contrast and nominal p=.036 can inform a new hypothesis. They cannot retroactively make the full-population primary endpoint successful. A future trial that prospectively enrolls a severe group would still need adequate randomization, a prespecified analysis and an outcome measured in all relevant participants under the planned rules.

The repeat-dose release adds another statistical distinction. Its primary prespecified ANCOVA comparison was not significant at p=.2. Additional two-sided t-tests gave different p-values, including .17 for repeat dose and .14 for single dose in the overall groups. A reader should not select the smallest p-value from several models and call that the original primary result. In the very-severe subset, the pooled active result was nominal p=.04, single dose .05 and repeat dose .08; the larger numerical repeat-dose change was not the most statistically precise result.

The severe repeat-dose comparison was small: 24 active participants pooled against 13 placebo, with only 10 in the repeat-dose arm. A single participant therefore represents 10 percentage points of that arm’s responder rate. The reported 60% CGI-I responder rate corresponds to six of ten people; 15% in placebo is rounded and arises from a different denominator. Such counts are useful for understanding fragility, not for asserting that a larger study must fail or succeed.

Safety also needs its denominator and exposure context. Five adverse-event discontinuations among 322 OLE participants is about 1.55%, rounded to 1.6%; it does not mean five treatment-related discontinuations, since the company attributed none to fasedienol. Likewise, no serious drug-related event is narrower than no serious event of any cause. Longer follow-up and broader populations can reveal findings not observed in an earlier program.

Finally, 197 month-four LSAS observations represent 61.6% of the 320 baseline observations. This is an observation-availability ratio, not a treatment retention rate: the disclosed early study closure prevented some participants from reaching month 4. The 31.4-point mean improvement describes the observations available at that time. It is not an intention-to-treat placebo-adjusted effect or evidence that 61.6% responded. The company’s 65% threshold-response figure uses the month-four assessment population and a different definition.

The PALISADE-2 registry lists 228 as actual enrollment, while the issuer reports 141 randomized participants in its efficacy result. These are source-specific counts; the randomized result above retains the issuer denominator rather than silently substituting the registry enrollment field.

03 The regulatory path and its unresolved timetable

Fasedienol remains investigational. The June-quarter filing describes a proposed new registrational trial and intended FDA discussion, rather than an accepted NDA or an assigned approval decision date. Previous Fast Track designation may support interaction with the agency; it does not establish efficacy or remove the need for adequate evidence.

Following PALISADE-4, Vistagen proposed evaluating repeated, as-needed use in everyday settings, with the LSAS measuring broader social-anxiety severity. This differs from a single clinic-based public speaking challenge assessed by SUDS. A shift in the clinical question can be reasonable, but it means the prospective study must establish its own endpoint, population, analysis and benefit-risk result. An OLE cannot establish that placebo-adjusted result.

Slide 33 of the September presentation proposes a U.S. multicenter, randomized, double-blind, placebo-controlled study of 350 adults aged 18–70. Fasedienol 3.2 micrograms would be used as needed up to six times daily over six weeks; the proposed primary endpoint is change from baseline in total LSAS score at week six versus placebo. CGI-S and PGI-C changes are proposed key secondary endpoints. The company explicitly says the design is to be finalized based on FDA feedback: publication of this proposal does not establish agency acceptance, financing or trial initiation. Proposed protocol, slide 33.

The September OLE disclosure still described preparing to meet FDA during the then-current quarter. As of October 4, that Q3 window has passed; Merlintrader has found no public announcement of a completed meeting or an agreed design. Absence of a public outcome is not proof the interaction did not happen. A useful next update would specify the population, randomized comparison, primary endpoint, sample size, funding and actual start schedule.

The June filing says the company believes it met minimum ICH E1 exposure recommendations, but had not aligned with FDA on specific exposure requirements for a potential NDA. Safety-database size and regulatory agreement are therefore distinct. The company closed the PALISADE-3 and 4 extensions in July for business reasons; the older registry estimates are not new readouts.

As of October 4, ClinicalTrials.gov still lists PALISADE-3 and 4 as active, not recruiting, with 238 actual participants each and estimated overall completion in October 2026 and April 2027. The repeat-dose record still says recruiting/60 estimated despite the company’s completed 61-participant result. These dated registry discrepancies are disclosed explicitly; issuer results describe the completed randomized populations. Refisolone’s April 2026 permission to proceed under its IND enables further U.S. development, not marketing. SEC clinical discussion.

04 Cash, dilution and the listing deadline

June cash and securities of $31.730 million covered about 2.16 quarters at the latest $14.707 million quarterly operating cash-use rate. This is a backward-looking ratio, not a forecast: trial redesign, staffing, working capital and financing could change it. The company guided funding into 2027, while its August 14 filing disclosed substantial doubt about continuing as a going concern within one year after issuance. The June cash-use figure was lower than June 2025; this comparison does not establish a lasting quarterly spending rate.

The June quarter raised $928,000 net through 1,580,176 ATM shares and $74,000 through 387,798 ESPP shares. Another 2,788,620 shares came from exercise of already-funded warrants at $0.001, bringing only about $3,000. These components reconcile the 4,756,594 increase in issued shares. It would be wrong to treat every new share as an economically equivalent fresh financing.

Issued shares increased from 29,286,585 at June 2025 to 44,381,433 at June 2026, a calculated 51.54%. Subtracting 4,522 treasury shares gives 44,376,911 outstanding, also reported on the August 10 cover. The nominal ATM capacity remaining at June 30 was about $139.5 million; this is authorization, not committed cash or assured execution capacity. The company also completed a separate $100 million gross/$93.5 million net underwritten offering in October 2023, so its financing history is not ATM-only.

June warrant counts were 9,294,022 T1 shares at $5.38 with stated August 29, 2026 expiry, and 11,265,086 T2 shares at $8.877 expiring October 4, 2028. Without a subsequent restatement, the passed T1 expiry reflects its disclosed contractual schedule, not a confirmed exercise or cancellation transaction. T2 permits cashless exercise. Ownership blockers constrain individual holders; they do not cancel the instruments.

Options totaled 5,249,249 at weighted exercise price $6.33, including 2,560,518 exercisable at $10.91. Their aggregate intrinsic value was zero at June 30. A zero intrinsic value is a dated valuation measure, not proof that the awards have no remaining economic value or can never be exercised. Adding all June warrants and options to June outstanding shares gives 70,185,268 potentially issued shares as an illustrative gross count. It is not GAAP diluted shares: 25,808,357 potential securities were excluded from diluted loss per share as anti-dilutive.

The insurance-premium note was repaid by June 30. The balance sheet still carries $783,000 of lease liabilities and material payables and accruals. Nasdaq’s August 4 extension set February 1, 2027 as the bid-price compliance deadline. The disclosed condition is a closing bid of at least $1 for at least ten consecutive business days; a failure can lead to a delisting determination and appeal. Conditional discussion of a reverse split is not an announced transaction. SEC statements and Notes 4–7.

Cash sensitivity and financing scale

For an illustration anchored to June 30, divide $31.730 million by three monthly operating-use assumptions. At the June-quarter average of $4.902 million per month, the ratio is 6.47 months. A 25% reduction gives about 8.63 months; a 25% increase gives about 5.18 months. These scenarios start from the June balance and do not represent remaining cash as of October. They exclude unknown subsequent financing, trial-start costs and changes in working capital. Management’s conditional runway guidance remains a separate forecast.

The latest quarter shows why loss and cash cannot be substituted. The $13.030 million net loss reconciles to $14.707 million operating cash use through noncash adjustments and working-capital movements. In particular, deferred revenue fell as earlier partner payments were recognized, while prepaid expenses increased. Licensing revenue therefore supported reported income without bringing an equal amount of new quarter cash. A model that subtracts net loss from liquidity would miss this distinction.

An illustrative $5 million equity raise at the rounded $0.28 historical price would require about 17.86 million new shares before fees or discounts. Relative to 44.376911 million outstanding, that is about 40.2% additional shares and about 28.7% of the resulting combined share count. These are different measures: new shares divided by old shares versus new shares divided by total shares. It is not a forecast of terms, financing feasibility or an announced transaction.

At a 20% lower hypothetical issue price, $0.224, the same gross amount would require about 22.32 million shares, approximately 50.3% of the old count. Cash received would be lower after fees, and any warrants could add a separate future dilution claim. Conversely, better pricing or non-equity proceeds could reduce share issuance. The purpose of the sensitivity is to connect a small market capitalization to financing scale, not to predict the next offering.

Liquidity is also narrower than total assets. June assets of $35.736 million included $2.580 million of prepayments and other current assets, plus equipment, a lease-use asset and other noncash items. These cannot all be assumed immediately available to pay trial invoices. Against $31.730 million of cash and securities, total recorded liabilities were $11.255 million. Subtracting them gives $20.475 million, but that is only an illustrative balance-sheet residual, not liquidation value or cash distributable to shareholders. Future operating costs and commitments would still consume resources.

Similarly, comparing the October third-party market capitalization of roughly $12.54 million with June liquidity does not establish that the business trades below current net cash. The dates differ by three months, and operating spending continued in between. The recorded liabilities, prospective trial costs, financing conditions and clinical uncertainty also matter. An updated valuation bridge would need to begin with the next reported balance and reconcile actual intervening financing and cash use before any value can be assigned to the development assets. This avoids converting a dated gross-cash ratio into a claim about current downside protection.

05 The other pipeline programs and funding priorities

Vistagen’s pherine platform extends beyond fasedienol to refisolone, itruvone, PH15 and PH284. Their proposed mechanisms involve nasal chemosensory pathways and downstream neural circuits. The mechanism is a development rationale, not proof of clinical efficacy across indications. Results in depression, menopausal symptoms or sleep deprivation cannot establish efficacy in social anxiety, even when molecules share a platform.

Refisolone: hot flashes and a separate PMDD study

The June-quarter filing confirms April 2026 FDA permission to proceed under the refisolone U.S. IND. Its earlier randomized, double-blind, placebo-controlled hot-flash study in Mexico enrolled 36 women, 18 per arm, with at least eight moderate-to-severe daily hot flashes. The company’s SEC presentation describes four weeks of as-needed dosing, 3.2 micrograms per administration and up to 16 micrograms daily. Improvement versus placebo was reported from week 1 through week 4, with p<0.001. This remains a small exploratory study rather than U.S. registrational evidence.

The related PMDD experiment is a different population and endpoint. The same presentation describes 52 women, six days of treatment and symptom scales including the Penn Daily Symptom Report. Its summary and detailed DSR slide give differing p-values, so they do not support a single precise estimate. The relevant conclusion is a reported exploratory signal requiring a prospectively defined development program; an IND for vasomotor symptoms does not itself establish a PMDD registration route.

Itruvone: numerical evidence exists, but it is early

It would be inaccurate to say that itruvone’s supporting study has no published sample size or effect estimates. The SEC presentation identifies a 30-patient randomized, double-blind, placebo-controlled Phase 2A depression study over eight weeks. The June 21, 2023 company release reports HAM-D-17 reductions of 10.1 points versus 4.2 placebo after one week in the 6.4 microgram group (p=.03), and 17.8 versus 10.9 at week 8 (p=.02, rounded). These are company-reported historical results, not evidence that a subsequent larger U.S. study has succeeded.

The between-group difference in the reported week 8 changes is 6.9 points, compared with 5.9 points at week 1. Those arithmetic differences describe that small study; they do not indicate expected effects in a broader population. The presentation reports an effect size of 0.95 at week 8 for the higher dose. The lower-dose result was not conventionally significant (p=.101). Dose selection, replication, duration and safety in a larger population remain material questions.

The 2023 U.S. Phase 1 release reported no serious adverse events or discontinuations due to adverse events; mild fatigue and headache occurred in one participant and resolved. Such a small healthy-volunteer safety study helps development planning but cannot establish long-term benefit-risk in patients with depression. The June 2026 filing describes pursuing further Phase 2 development, with resources and strategic considerations still relevant.

Other programs and the allocation constraint

PH15 targets psychomotor impairment associated with mental fatigue. The historical SEC presentation describes an exploratory randomized crossover study under sleep deprivation, comparing nasal treatment with placebo and oral caffeine. PH284 targets cancer cachexia; its exploratory study involved 40 female patients with terminal cancer. These programs have disclosed numerical experimental results, contrary to a blanket assertion that only adjectives exist. They remain early signals, and the current filing describes evaluating further development and work needed for U.S. INDs.

AV-101 is an oral asset rather than a pherine. The current filing says the company does not anticipate further development on its own and is considering a third-party path. A prospective partnership would need disclosed scope, economics and operational responsibility before it could be counted as a funded program.

AffaMed’s agreement concerns fasedienol rights in specified Asian territories. Its $5 million upfront was paid in 2020; up to $172 million of milestones are conditional, not available liquidity. Vistagen retains U.S. and other ex-territory rights. Fuji’s $1.5 million negotiation payment was received in 2023; the June 2026 quarter recognized the remaining $1.3 million when the negotiation period ended. Recognition of that old payment is not a new financing or proof of an executed commercialization license.

Historical SEC presentation, program data; Itruvone primary release; Current program and agreement disclosures.

06 Ownership, governance and market structure

Vistagen implemented an approximately 20% workforce reduction on March 5, 2026 to preserve cash while completing PALISADE work. Separately, its consulting agreement with former CFO Jerrold Dotson, initiated in August 2023 and amended, runs through December 31, 2026; expense was $30,000 in each June quarter of 2026 and 2025. These identify cost and related-party disclosures, not new efficacy evidence. Vistagen Form 10-Q (SEC). Vistagen SEC filing (March 5, 2026).

Mary Rotunno’s departure effective April 1, 2026 reduced the audit committee from three members to two, prompting a Nasdaq Rule 5605(c)(2) notice and a cure period. Margaret FitzPatrick and Joanne Curley later declined re-election. The September 10 annual meeting elected four directors and ratified KPMG for the fiscal year ending March 31, 2027. The April committee notice is a dated governance event, separate from the minimum-bid-price issue; these filings alone do not establish its October compliance status. Vistagen SEC filing (June 16, 2026). Vistagen SEC filing (April 1, 2026). Vistagen SEC filing (September 10, 2026). Vistagen SEC filing (March 17, 2026).

Angel S. Angelov’s May 18, 2026 CMO appointment carried a $425,000 annual base salary, a $50,000 signing bonus in two installments and an inducement grant of 150,000 options at $0.5955, vesting over four years subject to continued service. These are appointment-date compensation terms, not open-market purchases. Vistagen SEC filing (May 18, 2026).

The latest June-event ownership reports were filed August 14. Commodore reported 4,244,590 beneficial shares, 9.9%, but this is not 4.24 million ordinary shares alone: it includes 2,788,620 common shares, 1,394,310 T1 warrant shares and 61,660 T2 warrant shares. A further 1,628,354 T2 warrant shares were excluded under the ownership blocker. The denominator uses 41,032,453 common shares reported as of June 12 plus the included warrant shares. The manager, fund and two principals describe overlapping interests in the same securities; they are not separate stakes.

TCG Crossover Fund II reported 2,220,303 beneficial shares, 5.1%, entirely warrant shares: 1,003,718 T1 and 1,216,585 T2. Chen Yu reported an aggregate 2,960,404, 6.7%, across funds I and II. These positions therefore represent exercise rights as well as reported beneficial ownership, not a count of common shares bought in the market. The disclosed T1 expiry subsequently passed; the June reports are historical and cannot establish the October holding without a new filing. OrbiMed reported zero as of June 30. None of these disclosures by itself establishes an investor’s clinical opinion.

Commodore primary 13G/A; TCG primary 13G/A; OrbiMed primary 13G/A.

The July 31 proxy reports 1,334,934 beneficial shares for eleven executive officers and directors, 2.93%, on its specified July 22 base and beneficial-ownership rules. This is distinct from the 0.42% insider ownership figure in third-party market data. Neither should silently replace the other. Option rights, scope and dates can differ. The proxy also identifies Nick Tressler as CFO and Treasurer since December 2025; the prior interim-CFO arrangement is historical.

The proxy describes executive option awards, including the December 1, 2025 CFO inducement of 150,000 at $4.43. An option grant compensates service and differs from an open-market purchase. The June quarter’s company-wide option total and compensation expense are described in the finance section; there is no claim here that every historical insider transaction has been exhaustively excluded. Shawn Singh remains President and CEO, and Angel Angelov is Chief Medical Officer, according to company disclosures.

The June-quarter filing records five shareholder actions: one California action dismissed with prejudice and four other actions, including consolidated derivative litigation, described in its legal-proceedings section. The company disputes the allegations. A complaint is not an adjudicated finding, and the filing’s August status does not establish every later docket development. Litigation can absorb resources alongside a constrained clinical budget; any recovery or liability amount remains unknown.

The September 15 short position was 2,707,020 shares against average daily volume 354,148, yielding about 7.644 days to cover. Relative to 1,410,489 on March 31, the position increased 91.92%, and relative to 1,338,753 on October 15, 2025 it increased 102.20%. Those are arithmetic comparisons of dated observations. Days to cover changes with its volume denominator and does not predict how long covering would take in a different market. Float, short interest and third-party ownership figures do not prove current trading depth or an exclusive ownership partition.

What the proxy measures

The July proxy makes the composition of management ownership clearer than a single percentage. Of the group’s 1,334,934 beneficial shares, 165,408 were common shares and 1,169,526 were options exercisable within the applicable sixty-day window. Options therefore represented approximately 87.6% of this disclosed beneficial total. That calculation describes the proxy’s ownership convention; it does not mean the group had already paid to exercise those options, owned that many issued common shares, or committed to buying shares in October. Each holder’s beneficial percentage also adds that holder’s exercisable rights to the relevant denominator, so percentages should not be recomputed indiscriminately against a single unadjusted common-share base.

For CEO Shawn Singh, the proxy reports 629,172 beneficial shares, comprising 75,721 common shares and 553,451 exercisable options. The common component includes 20,875 held through a trust. CFO Nick Tressler’s disclosed 11,712 shares were common shares. These are different exposure structures. An investor assessing alignment should distinguish common equity already held, exercise rights requiring a payment, vesting conditions and the price at which those rights become economically attractive. None of these figures proves a recent discretionary market purchase or predicts how an officer will vote, trade or finance the company.

Compensation requires a similar separation. For the fiscal year ended March 31, 2026, Singh’s reported total was $1,212,560, including $650,000 salary and $562,560 of option-award accounting value, with no bonus in the table. The option value is a grant-date accounting estimate, not cash paid out at that value and not a realized investment gain. Treating the entire reported total as current cash salary would overstate cash compensation; treating the equity component as costless would ignore the compensation claim and potential dilution.

Tressler’s $866,516 total covered a partial fiscal year and included $150,000 salary, a $50,000 signing bonus, $641,790 option-award value and $24,726 of consulting fees. It does not represent a full year of recurring salary. The signing payment also shows why a statement that management received “no bonuses” would be too broad. Following the PALISADE-3 result, the board forewent the annual performance bonuses and salary increases described in the proxy, but inducement payments and subsequent retention decisions were separate categories.

The proxy further describes retention payments for Tressler, Cote and Prince approved and paid before the annual meeting, relating to fiscal 2027; Singh and Adler declined retention payments. Those later amounts were to be disclosed in the next proxy. This creates a specific follow-up question: how do subsequent disclosed compensation costs compare with the company’s revised operating plan? The available document supports the existence and category of those decisions, not an invented October cash total. The next filing will show actual payments and equity expense; their size cannot be reliably inferred from the prior-year table.

For the clinical budget, the June filing separates $6.803 million of clinical and nonclinical fasedienol expense from $0.195 million for other candidates, alongside personnel and other research costs. The comparable program amounts were $7.771 million and $0.261 million a year earlier. The fasedienol program line declined approximately 12.5%, while total R&D declined about 6.6%, from $11.678 million to $10.906 million. The difference matters: reducing trial invoices does not reduce every payroll, facilities or support cost at the same rate. These are accrual expenses, not a direct measurement of cash paid for trials. A new protocol would need both a clinical plan and a budget that reconciles program costs with the wider operating structure. Proxy ownership and compensation tables; June-quarter R&D discussion.

07 Evidence checkpoints

The first clinical checkpoint is a disclosed FDA interaction and prospective trial design. Watch for inclusion criteria, endpoint hierarchy, randomized comparator, statistical plan, sample size and funding. The prior Q3 discussion window has passed; an intended meeting is not the same as an outcome or an accepted protocol.

The next financial report will be the reference for updated liquidity, ATM issuance, actual cost reductions and the remaining warrant count after the scheduled T1 expiry. A June balance plus a later financing announcement does not amount to a complete October cash statement. Nasdaq compliance has a February 1, 2027 deadline, while clinical timing remains less precise. These calendars can constrain one another without making the listing event a clinical catalyst.